The size of the aptamers market in Europe is expected to reach USD 155.8 million by 2028 from USD 62.65 million in 2023, growing at a CAGR of 20% from 2023 to 2028.
The low cost and high efficiency of aptamers in binding to large molecules compared to antibodies, coupled with an increased focus to improve the technology primarily drive the aptamers market growth in Europe. In addition, introducing a chemical modification approach to increase aptamer nuclease resistance and, as a result, therapeutic characteristics opens up a slew of opportunities for aptamer market players. Continuous growth in demand for aptamers and associated products from research institutes has resulted from this. In addition, aptamers have been used as medicines and drug carriers due to ongoing research and development, and their use as diagnostic instruments provides new growth opportunities for producers.
Additionally, the various advantages that these small molecules offer over traditional antibodies have led to the growing demand for these compounds in various therapeutic applications. For example, aptamers will be used as biosensors in the food and beverage industry in the future years, with a projected scope in the food and beverage sector. Moreover, the numerous benefits that these small molecules provide over conventional antibodies have resulted in increased demand for these compounds in various medicinal applications.
In addition, the Continuous advances in selection strategies will continue to drive the aptamer market forward. For example, long repetitive stages were used in the traditional Systemic Evolution of Ligands by Exponential Enrichment (SELEX) approach, delaying probe selection and slowing the selection process further. Furthermore, because time efficiency is so important in the healthcare sector, many research institutions invest in developing cost- and time-effective selection techniques.
On the other hand, manufacturers have avoided using these molecules due to a lack of understanding about aptamers and technical expertise. Furthermore, aptamers have a limited half-life (minutes to hours), making them difficult to create therapies.
This research report has been segmented and sub-segmented the European aptamers market into the following categories:
By End User:
Geographically, the European market had the second-largest share in the global aptamers market in 2020 and is forecasted to account for a promising share during the forecast period. Increasing focus on the research and development activities in the pharmaceutical and biotechnology sector to introduce advanced various pharmaceutical drugs is fuelling the market growth. Further, advancements in aptameric systems bode well for developing effective and cheap diagnostics, treatments, and preventive vaccinations for SARS-CoV-2 and other infectious diseases. As a result, the major countries in the region, such as Germany, the UK, France, and Italy, are expanding the European regional market growth.
The German aptamers market held the largest share of the European market and is likely to continue the dominant during the forecast period owing to the increasing prevalence of advanced technological base associated with the growing investments and funding for technology development.
However, the UK aptamers market is anticipated to grow at a healthy CAGR during the forecast period. The increasing incidence of life-threatening diseases such as Cancer has directed many companies to introduce new & effective detection assays based on aptamer therapy which is expected to expand the market growth.
Similarly, the countries such as Italy, France, and Spain are projected to showcase a moderate CAGR in the European aptamers market during the forecast period owing to the increasing investment by the biotechnology and pharmaceutical industries in research and development activities.
KEY MARKET PLAYERS:
Major companies dominating the European aptamers market are AM Biotechnologies, Aptagen, Aptamer Sciences Inc., Aptamer Solutions Ltd., Aptus Biotech S.L., Base Pair Biotechnologies Inc., NeoVentures Biotechnology Inc., SomaLogic Inc, TriLink BioTechnologies Inc., and Vivonics, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com